Background {#Sec1}
==========

Chronic granulomatous disease (CGD) is a rare, inherited primary immunodeficiency which affects approximately 1/250,000 worldwide \[[@CR1]\]. CGD is categorized into two main subtypes, viz. X-linked and autosomal recessive (AR), based on the mode of inheritance. Overall, about 65% of CGD cases worldwide are X-linked type while the remaining 35% are autosomal recessive CGD cases \[[@CR2]\]. However, in certain regions with high degrees of consanguineous marriages, AR-CGD is more prevalent \[[@CR3]\].

Chronic granulomatous disease is caused by a defect in phagocytic cells (neutrophils, macrophages, and monocytes) which fail to exhibit the 'respiratory burst', the rapid increase in oxidative metabolism following phagocytosis, thereby failing to effectively destroy invading pathogens. This is due to a germ line mutation in one of the five genes which code for the five subunits of the NADPH oxidase enzyme complex \[[@CR1]\].

X-linked recessive CGD occurs due to mutations in the *CYBB* gene which encodes gp91*phox* subunit. Mutations in the genes encoding the subunits p47*phox*, p67*phox*, p40*phox*, and p22*phox* (*NCF1, NCF2, NCF4*, and *CYBA* respectively) are responsible for AR-CGD \[[@CR4]\]. The most common form of AR-CGD accounting approximately 90% of all AR-CGD cases is due to mutations in *NCF1* gene. The predominant mutation found in these patients is a GT deletion in the GTGT repeat sequence at the beginning of exon 2 of *NCF1* \[[@CR5]\].

The first CGD case was reported in Sri Lanka in 1999 \[[@CR6]\]. There is a paucity of clinical data of CGD patients in Asian countries, especially South Asia. Large multi-centre studies have been carried out in Western countries, and CGD databases have been established in Europe, USA and Latin America. However, Western data might not be applicable for Asian countries due to differences in social practices (e.g. consanguineous marriages) and endemic infections. We report on the patients with CGD in Sri Lanka, and evaluate the clinical scenario and evolution of the disease in a developing country.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Ethics clearance was obtained from the Ethics Review Committee of the Medical Research Institute (No 05/2016 and 06/2016), and informed written consent was obtained from the parents of the patients.

Thirteen patients with CGD from 11 families were seen at Immunodeficiency Clinic at Medical Research Institute (MRI), Colombo Sri Lanka, from 2004 to December 2017. Their diagnoses were based on \< 5% normal neutrophil activity with the nitroblue tetrazolium (NBT) reduction slide assay. Eleven out of thirteen patients were referred to the Immunodeficiency clinic owing to multiple recurrent infections. The two remaining patients were referred to the clinic, within days of birth due to recurrent infant deaths in the family. Clinical details of the patients, including details of deceased siblings, were obtained from the case records.

Genomic DNA analysis {#Sec4}
--------------------

Three millilitres of blood was collected into tubes containing EDTA from eight CGD patients after informed written consent was obtained. Genomic DNA was extracted from whole blood stored in EDTA using commercially available QIAmp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) following manufacturer's protocol. Previously described \[[@CR7]\] exon specific oligonucleotide primers for *NCF1* (2LB2 and 2RB2) were purchased from Integrated DNA Technologies (Iowa, USA). Thirteen sets of exon specific primers for the *CYBB* gene were kindly donated by Prof Yu-Lung Lau of University of Hong Kong. The amplified DNA fragments were subjected to bi-directional sequencing with BigDye^®^ Terminator v3.1 cycle sequencing kit and resolved with direct sequencing on an automated fluorescence sequencer, Applied Biosystems^®^ 3500 Dx Genetic Sequencer.

cDNA analysis by RT-PCR {#Sec5}
-----------------------

Human total leukocytes were isolated from EDTA-whole blood using dextran sedimentation method, which is based on differential centrifugation principle, as previously described \[[@CR8]\]. Total RNA was extracted from separated leukocytes using TRIzol^®^ reagent as per the manufacturer's guidelines. First-strand cDNA synthesis was performed from total RNA using random primers and the cDNA was immediately amplified into three overlapping fragments. The amplified products were subjected to bi-directional sequencing as described above.

Results {#Sec6}
=======

Demographics and family history {#Sec7}
-------------------------------

Eleven patients of the 13 analysed were males while the remaining two were females. The patients originated from 5 districts across the country. The patients comprised of all major ethnic groups of the country, 9 Sinhalese, 2 Tamil, and 2 Muslim patients. The ages of the patients ranged from 3 days to 14 years at the time of sampling. The participants of the present study were diagnosed between 2004 and 2017.

The thirteen CGD patients belonged to eleven families. P-01 and P-12 were brothers while P-05 and P-06 were brother and sister. Four families had consanguineous parents. Four patient families had reported 7 previous sibling deaths (Table [1](#Tab1){ref-type="table"}). All of the sibling deaths occurred during infancy or very young age. In the family of P-01 three elder died due to sepsis. Although not diagnosed, two of the three siblings may have died of complications of CGD. The third sibling had been diagnosed with CGD (P-12), and was on prophylactic treatment. Furthermore, the mother of P-01 (and P-12) reported that three of her siblings passed away during infancy.Table 1Family history and clinical manifestations in CGD patientsPatientConsanguinitySibling deathsAge at manifestationClinical manifestationP-01YesC1 (M) Died at 4 months after febrile illness\
C2 (M) Died at 2 months. Post mortem examination revealed numerous caseating granulomata of lung and pleural tissue, consistent with bronchopneumonia due to tuberculosis (TB) (or *Mycobacterium bovis* following BCG)\
C3 (M, P-12) Diagnosed with CGD. Died at 3 years1 monthPositive NBT. Diagnosed with CGD. On anti-microbial prophylaxisP-02NoNo siblings1½ monthsOtitis media and meningitis2½ monthsSepticaemia. Treated with meropenem for 7 days3 monthsLeft axillary lymph node abscess. Anti-TB category I and II for 1 year4 monthsRight upper lobe pneumonia, otitis mediaOral thrush twice while on IV antibiotics7 monthsPositive NBT. Diagnosed with CGD. Prophylaxis commenced. Started anti-TB treatment2 yearsDied following stem cell transplantationP-03NoC1 (M) Healthy12 daysNasal vestibulitis. Treated with IV Augmentin27 daysMultiple skin abscesses on hands and feetRight elbow joint osteomyelitis2 monthsLRTIPositive NBT. Diagnosed with CGD. Prophylaxis commenced5 monthsSkin abscesses on right forearm and left buttock7 monthsSkin abscesses, pus discharge from BCG scar site, left axillary lymphadenopathy. Mantoux \> 10 mmP-04NoC1 (F) Healthy\
C2 (M) Died at day 11 due to septicaemia16 daysFever, pyelonephritis, septicaemia, cellulitis, cervical lymphadenopathy, hepatosplenomegaly, and skin rash. Blood culture was positive for *B. cepacia* and *Candida albicans*43 daysFever. Chest X ray revealed inflammatory changes. Lymph node biopsy revealed epithelioid cells and necrotizing inflammatory material. He was commenced on anti TB therapy2 monthsPositive NBT. Diagnosed with CGD. Anti-microbial prophylaxis initiatedP-05YesC1 (M) Died at 1 year 3 months after febrile illness6 monthsLRTI10 monthsMiddle mediastinal mass. Biopsy indicated caseous necrosis. Compatible with TB, treated with anti-TB therapy11 monthsPneumonia2 yearsRecurrent oral ulcers2 years 7 monthsPositive NBT. Diagnosed with CGD. Started on anti-microbial prophylaxis5 years 7 monthsOral thrushP-06YesSibling of P-051 year 8 monthsUrinary tract infection (culture positive)Multiple episodes of pneumonia, meningitis. Cervical lymphadenopathy4 yearsRight cavitatory pneumonia, failure to thrive6 yearsLeft lower eye lid abscess and cellulitis*Pseudomonas aeruginosa* septicaemiaEcthyma gangrenosum, parotitisPositive NBT. Diagnosed with CGD. Anti-microbial prophylaxis initiated10 yearsLRTI. Sputum negative TB. Anti-TB therapy category I and later II commenced11 yearsHRCT Chest---early parenchymal and interstitial lung fibrosis mainly affecting upper lobes, and bronchiectasis of lower lobes14 yearsBronchopneumonia, blood culture revealed *C. parapsilosis*LRTI15 yearsLRTI, abscessesP-07NoNo siblings1 monthsPoorly resolving pneumonia, high fever spikes2½ monthsMultiple skin abscessesPositive NBT. Diagnosed with CGD. On anti-microbial prophylaxis4 monthsAbscesses occurred in scrotum, cheek and liver1 year 2 monthsBlood stained stools. Right inguinal lymphadenopathy3 yearsAnal fissureInguinal lymphadenopathy. Excision biopsy revealed granulomata and central suppurative necrosis3½ yearsPoorly resolving pneumonia (right middle lobe and lower lobe consolidation). Mantoux 18 mmAnti-TB category I commenced4½ yearsMiddle/left lobe pneumonia5 yearsPustules on the face. On itraconazole and cotrimoxazole prophylaxisP-08NoC2 (M) Healthy7 monthsDysentery8½ monthsLRTI1 year 9 monthsFever of unknown origin (21 days)3½ yearsMediastinal mass. Biopsy revealed extensive caseous necrosis. Acid fast bacilli not seen. Mantoux negative. Anti-TB therapy category I commenced (7 months)3 years 9 monthsLeft lower lobe pneumonia4 yearsRight middle lobe pneumonia, lymphadenopathy4 years 5 monthsAnaemia, hepatosplenomegaly. Treated with Iron (7 months)4 years 8 monthsFever, erythematous pustular rashes on lower limbs. Bone marrow showed increased lymphoplasmacytic activityPerihilar lymphadenopathy. TB culture, TB-PCR negative. Query---relapse of TB. Started on anti-TB therapy category II (7 months)5½ yearsFever for 1 month while on category II anti-TB therapy. Multiple areas of consolidation in lungs, mediastinal lymphadenopathy and hepatosplenomegaly. CT thorax guided biopsy---granulomatous inflammation suggestive of TB. Acute bronchopneumonia6 years 4 monthsPositive NBT. Diagnosed with CGD. Prophylaxis commencedP-09YesC1 (M) Healthy\
C2 (F) Healthy3 daysFever, mild jaundice. Treated with IV antibiotics2 monthsMeningitis, bronchopneumonia. Treated with IV antibiotics3 monthsLRTI. Treated with IV cefotaxime4 monthsLRTI8 monthsFever, meningitis. Mantoux 26 mm. Anti-TB therapy started11 monthsPositive NBT. Diagnosed with CGD. Prophylaxis commenced2 yearsPatient expiredP-10NoC1 (M) Died at 1½ years following possible pneumonia\
C2 (F) Healthy\
C3 (M) Died at 1 year 2 months following possible pneumonia\
C4 (M) Healthy\
C5 (F) Healthy1 year 1 monthRight middle lobe pneumonia, lung abscessPositive NBT. Diagnosed with CGD. Prophylaxis commenced4 yearsLRTI and perineal abscess6 yearsBronchopneumonia7 yearsSkin abscesses over right knee joint9 yearsCystitis, splenomegaly10 yearsPatient expiredP-11YesNo siblings1½ monthsSevere failure to thrive, bilateral granulomatous cervical lymphadenitis. Defaulted anti-TB treatment4 monthsPoor weight gain. Tonic convulsions, sepsis, hepatosplenomegaly. TB meningitis suspected. PCR of gastric aspirate for mycobacteria (GeneXpert) negative. Anti-TB therapy commenced6 monthsPositive NBT. Diagnosed with CGD. Prophylaxis commenced1 yearPatient expiredP-12YesElder sibling of P-012 monthsAdmitted with febrile illness, and treated for sepsis with IV antibiotics for 21 days. Itraconazole and cotrimoxazole prophylaxis8 monthsSkin abscess after DTP dose 3, liver abscess, fever, iron deficiency anaemia. IV antibiotics for 1 week. Liver abscess drained11 monthsPositive NBT. Diagnosed with CGD2 years 3 monthsMeasles, fever, respiratory features, abdominal distension. Treated with IV antibioticsMesenteric and paracentric lymphadenopathy. Anti-TB therapy commenced. Pus culture from abdominal wall abscess positive for MRSA3 years 3 monthsLiver abscess, lymphadenopathy. Patient expired due to possible TB compilationsP-13NoNo4 monthsSkin abscessesPoor wound healing6 monthsBronchiolitis7 monthsPyrexia*Pseudomonas aerugenosa* isolated from wound swabPositive NBT. Diagnosed with CGD. Prophylaxis commenced

Clinical course {#Sec8}
---------------

Eleven patients were referred to MRI due to recurrent unresolving infections while P-01 and P-12 (siblings) were referred owing to their family history. The mean age at onset of disease among the patients is 4.6 ± 5.6 months. Majority of the patients (58%) manifested symptoms as early as 2 months since birth, out of which 3 patients developed symptoms during the first 2 weeks. In X-linked CGD patients, the mean age at onset was 1.5 ± 1.3 months and in AR-CGD patients 12 ± 8.5 months.

The mean age at diagnosis for the entire cohort was 18.6 ± 25.8 months. Most patients (69%) were diagnosed in infancy. The mean age at diagnosis was 4.6 ± 3.7 months in X-linked CGD patients and 51.5 ± 29.0 months in AR-CGD patients. The mean diagnostic delay irrespective of subtype was 15.5 ± 22.8 months.

Five out of 13 patients (38%) have died, at an average of 3.65 ± 3.63 years. Only 2 of the deceased patients (P-02, P-12) are known to have X-linked CGD. P-02 died following stem cell transplantation.

Clinical manifestations {#Sec9}
-----------------------

Respiratory tract was the most prevalent site of clinical manifestations. Eleven patients (85%) had respiratory tract infections, including bronchopneumonia (69%). Six patients (46%) had more than one episode of pneumonia. One patient had bronchiectasis (8%). After respiratory tract manifestations, the skin was the organ most affected. Ten patients (77%) developed multiple skin abscesses on the face, neck, and limbs and to some lesser extent skin rashes, ecthyma gangrenosum, and pustules. Other deep seeded abscesses include liver abscesses in 2 patients (15%) one of whom had 2 episodes, lymph node abscesses in 2 patients (15%) and lung abscess in one patient (8%).

Lymph node manifestations were observed in 8 patients (62%), of which 6 patients had multiple episodes of lymphadenopathy. Meningitis affected 4 patients (31%), of which one patient developed multiple episodes. Septicaemia was reported in 5 (38%) patients although the causative pathogen was not identified in the majority.

BCG vaccine was administered at birth to 11 patients (85%) in the group except for P-01 and P-12 (siblings) owing to their family history of infant deaths. Two patients developed adverse reactions to the vaccine. For instance, P-03 developed an adverse reaction at the BCG scar site along with left axillary lymphadenopathy and a positive Mantoux test, suggestive of possible infection with *M. bovis.* Furthermore, mediastinal masses with caseous necrosis was seen in two patients (P-05 and P-08) indicating disseminated mycobacterial infections. Two patients were diagnosed with tuberculous meningitis, one of whom had a positive Mantoux test (26 mm). Ten (77%) patients received anti-TB therapy despite not being able to isolate the organism.

The patients were commenced on prophylaxis antimicrobials; mainly itraconazole and cotrimoxazole, without delay upon their diagnosis. However, 5 (38%) patients developed multiple infections and manifestations such as LRTI, lymphadenopathy, skin abscesses despite prophylactic treatment. Interferon gamma therapy is not offered in Sri Lanka. One patient (P-02) who underwent stem cells transplantation died following the procedure.

Mutation analysis {#Sec10}
-----------------

Eight CGD patients (7 males and 1 female) who were laboratory confirmed by slide NBT assay were included in the mutation analysis. Point mutations in *CYBB* gene were identified in 06 patients confirming their X-linked CGD status. The detected mutations in *CYBB* gene includes, deletions, nonsense and a novel splice site mutation as summarized in Table [2](#Tab2){ref-type="table"}. In P-07 no exonic mutations were identified. However, a novel T \> A nucleotide substitution (c.141+6T \> A) was detected 6 bases downstream from end of exon 2 in the intron 2 region. Analysis of the patient's cDNA revealed that this novel mutation is a pathogenic splice site mutation, which resulted in exon skipping by the deletion of the entire exon 2 (Fig. [1](#Fig1){ref-type="fig"}).Table 2Summary of clinical details and genetic analysis of CGD patientsPatientCGD subtypeSlide NBT result (%)Age at onsetAge at diagnosisGene affectedExon/intronNucleotide changeAmino acid change \[[@CR9]\]P-01X-linked\< 5Referred at birth1 month*CYBB*Exon 10Deletion c.1314delGp.Ile439SerfsX63P-02X-linked\< 51.5 months6.5 months*CYBB*Exon 11Deletion c.1415delGp.Gly472AlafsX30P-03X-linked\< 51 month7 months*CYBB*Exon 10Deletion c.1314delGp.Ile439SerfsX63P-04X-linked\< 516 days2 months*CYBB*Exon 3Nonsense c.217C \> Tp.Arg73XP-05AR\< 56 months2.5 years*NCF1*Exon 2Deletion c.75_76delGTp.Tyr26HisfsP-06AR\< 51.6 years10 years*NCF1*Exon 2Deletion c.75_76delGTp.Tyr26HisfsP-07X-linked1--21 month2.5 months*CYBB*Intron 2Splice site c.141 + 6T \> Adel exon 2\
p.Leu16_Gly47delP-13X-linked\< 54 months7 months*CYBB*Exon 3Splice site c.252G \> Adel. exon 3\
p.Ser48_Ala84del Fig. 1Exon skipping in P-07. The novel splice site mutation identified resulted in the deletion of the entire exon 2 region of the *CYBB* cDNA in P-07. The figure shows the deleted region when the patient cDNA (bottom) is aligned with a reference sequence (top) (NCBI Accession: NC_000023.9)

The two remaining patients (P-05 and P-06) were classified as AR-CGD cases, based on the detection of the prominent homozygous GT deletion (c.75_76delGT) mutation in *NCF1* gene.

Discussion {#Sec11}
==========

The majority of the Sri Lankan patients studied, were X-linked CGD cases (75%) similar to other studies in Western countries \[[@CR1], [@CR10], [@CR11]\] and in contrast to South Asian (Indian) and other Asian countries such as Turkey and Iran, where AR-CGD is reported with a higher frequency than X-linked CGD \[[@CR3], [@CR12]\] (Table [3](#Tab3){ref-type="table"}). Although consanguineous marriages are responsible for this high rates of AR-CGD in Turkey and Iran, consanguinity was not frequent among the Indian patients (2/17), and the higher prevalence of AR-CGD may be due to high incidence of autosomal recessive mutations resulting from marriages being restricted to close-knit communities \[[@CR2]\]. Interestingly, 6 patients from 4 families reported to have consanguineous parents in the Sri Lankan cohort, although only 2 patients were positively confirmed with AR-CGD.Table 3Comparison of patient cohort demographics of different CGD studiesCountry/regionNumber of patientsGenderConsangui-nityCGD subtypeDeathsMaleFemaleX-linkedARSri Lanka121026 (46%)6 (75%)2 (25%)4 (38.4%)India \[[@CR2]\]171522 (11.7%)7 (41%)10 (59%)6 (35%)Iran \[[@CR12]\]41291223 (56.1%)5 (12.2%)Turkey \[[@CR3]\]89642542 (57.5%)34 (38.2%)55 (61.8%)9 (10.1%)China \[[@CR14]\]48444036 (75%)3 (6%)11 (22%)Latin America \[[@CR10]\]715813--53 (74.6%)18 (25.3%)--Europe \[[@CR1]\]42935178--290 (67%)139 (33%)84 (20%)USA \[[@CR11]\]36831652--259 (70%)81 (22%)65 (17.6%)

The overall mortality (38%) was higher than in India (35%), and in the West \[[@CR1], [@CR2]\]. The mortality in a large cohort of 429 patients from Europe was 20% \[[@CR1]\], whereas in an Italian cohort the mortality was 13% \[[@CR13]\].

The onset of symptoms in the patient cohort was very early (mean 5½ months) compared with other studies; 20 months in India \[[@CR2]\] and 23.9 months in Latin America \[[@CR10]\]. Majority of the CGD patients (85%) developed at least one unusual or severe infection within the 1st year of life. Seventy seven percent of the local cohort was identified by unusual susceptibility to severe infections before the age of 2 years. In China 90% of the patients had an onset within 3 months of birth \[[@CR14]\]. The mean age at diagnosis of Sri Lankan patients was 1.6 years. This is lower than other countries; India 4½ years \[[@CR2]\], Iran 6.3 years \[[@CR12]\], Turkey 4.2 years \[[@CR3]\], China 2.24 years \[[@CR14]\], Europe 4.9 years (X-linked), 8.8 years (AR) \[[@CR1]\]. This may be due to early exposure to infections, genetic phenotype, or easy access to basic healthcare in the country. Additionally, the mean diagnostic delay in local patients was about 15 months, which is significantly lower than the 3.9 year delay in Iran \[[@CR12]\].

Large scale CGD studies have shown that the disease manifests earlier in X-linked CGD compared to AR-CGD \[[@CR1]\]. Similarly, the mean age of diagnosis is lower in the patients with X-linked CGD compared with those with AR-CGD. For instance, the mean age at diagnosis in patients with X-linked CGD versus AR-CGD are 4.9 vs 8.8 years in Europe, 3.0 vs 7.8 years in USA, and 2.7 vs 5.2 years in Turkey \[[@CR1], [@CR3], [@CR11]\]. The mean age at diagnosis in our study was 4.6 months for X-linked CGD while it was 4 years and 3 months for AR-CGD. Despite the small size of the cohort in Sri Lanka, the onset of disease was early (1.5 months) in X-linked CGD patients compared to AR-CGD patients (12 months). All of these findings suggest a milder phenotype or a delay in clinical presentation in AR-CGD.

The clinical presentation and manifestations in the local cohort appear to be comparable with regional and global trends. Most large cohort studies report pulmonary manifestations to be the most common (Table [4](#Tab4){ref-type="table"}). In the local cohort 85% had lower respiratory tract infections. Seventy seven percent of the patients had skin/subcutaneous infections while 62% reported lymph node involvement. These figures seem to correlate with other worldwide figures \[[@CR1], [@CR3], [@CR10]\]. Gastrointestinal manifestations such as inflammatory bowel disease were not seen in our patients. In addition, chronic lung disease, including bronchiectasis and fibrosis was seen in only one patient. This is in contrast to other cohorts, where it is more common \[[@CR15]\].Table 4Comparison of clinical manifestations in CGD patientsSite of clinical manifestationPrevalence in different countries/regions---proportion (percentage) (%)Sri LankaIndia \[[@CR2]\]Iran \[[@CR12]\]Turkey \[[@CR3]\]China \[[@CR14]\]Latin America \[[@CR10]\]Europe \[[@CR1]\]USA \[[@CR11]\]Lung*8582*66*8377776679* Pneumonia81 Pulmonary TB18 Lung abscess9 Lung fibrosis/bronchiectasis27Skin/subcutis7747634546425342Lymph nodes62*8276*6550595053Liver4659--638--3227 Liver abscess33 Hepatosplenomegaly83GI tract31355622544248-- Diarrhoea/dysentery50 Oral ulcers25 Parotitis25Urinary tract236--222202210Septicaemia3825--3023232018Ear812242282914--Osteomyelitis81829234161325Meningitis31--2174--74 TB meningitis25BCG complications8--172253308--The most common manifestations reported in each cohort are indicated in italic text

The spectrum of microorganisms implicated in causing infections may vary slightly in different regions, but the most common pathogens reported worldwide are *Staphylococcus aureus*, *Burkholderia cepacia*, *Serratia marcescens*, *Nocardia,* and *Aspergillus* sp. \[[@CR16]\]. The Indian study reports *Aspergillus* to be the most common organism isolated in patients followed by *Staphylococcus aureus, Burkholderia cepacia* and *Candida* \[[@CR2]\]. However, in Sri Lanka, the causative agent had not been isolated in majority of instances. Due to lack of facilities, bronchoscopy or direct lung biopsies are not routinely done. The patients were often managed in peripheral hospitals, with no input from an Immunologist. Many of the infectious complications occurred before an Immunological diagnosis. *B. cepacia* and *Candida* were isolated from blood in P-04. *Candida* was also isolated from an oral swab two patients with oral thrush, while, septicaemia caused by *Pseudomonas* was reported in P-06. *Pseudomonas aerugenosa* was isolated from a wound swab from P-13. *Aspergillus* sp. was the main pathogen responsible for pulmonary infections in CGD patients in Europe, France, Turkey, and India \[[@CR1]--[@CR3], [@CR17]\]. The lack of reported *Aspergillus* infections in the Sri Lankan cohort is surprising and highly unlikely, suggesting more thorough microbiological examinations are required.

The clinical data collected in the Asian Primary Immunodeficiency (APID) network database suggest that *Mycobacteria tuberculosis* and *M. bovis* infections are significant in Southeast Asian CGD cohorts \[[@CR18]\]. Furthermore, a retrospective study on CGD patients with mycobacterial disease from Latin America, Africa, Europe, and Asia, revealed that 44% had TB \[[@CR19]\]. In the Chinese cohort of 17 patients, 7 had TB while 8 had BCG complications \[[@CR20]\]. Pulmonary tuberculosis was recorded as the second common respiratory involvement (31.7%) in the Iranian cohort \[[@CR12]\]. In the Indian cohort, *Mycobacterium* was detected in only one patient, while two more were treated for TB \[[@CR2]\].

In Sri Lanka, ten (77%) CGD patients received anti-TB medication at some point in their treatment. The decisions to treat were based on biopsy findings in 5 patients, Mantoux positivity in 3 patients, and X-ray evidence in 2 patients. Facilities for AFB staining, Mantoux, culture, PCR and T spot (IGRA) are available in Sri Lanka, but are not routinely done. Using the acid fast stain on biopsies is generally not done, unless specially requested. Culture is generally done with sputum, but not generally from tissues. In addition, differentiation of *M. bovis* from *M tuberculosis* is not done. PCR (GeneXpert) is performed, but not done routinely due to the cost. On a few occasions PCR and culture were performed. Most often, it was a clinical diagnosis based on BCG immunization, location of lymphadenopathy, presence of necrosis/caseation, and Mantoux (\> 10 mm). Interestingly, none of the patients were positive for *Mycobacterium* cultures. TB PCR and acid fast staining were negative. BCG vaccine is given to all infants at birth, and the coverage is 99% in the country \[[@CR21]\]. In our cohort, BCG vaccine was given to 11/13 patients. While facilities are available for categorizing BCG infection as definitive, probable, possible, and ruled out (European Society for Immunodeficiencies---ESID criteria) \[[@CR22]\], it was not availed of in all instances. In many instances, the diagnosis of BCG/mycobacterial infection was done prior to referral to our clinic. With the clinical history, it is probable that the positive Mantoux was due to infection with *M. bovis*. The diagnosis would fit the possible category (ESID criteria). The BCG strain used the vaccine in Sri Lanka is sensitive to all drugs except pyrazinamide. As the 4 drugs are given in one capsule, pyrazinamide is also administered. The duration for anti TB therapy was the standard regime. ESID suggests 3 drugs for BCG it is in patients with SCID, and continuation till complete immunological reconstitution occurs after HSCT (in SCID for example). For BCGosis, anti-TB treatment including four or more anti-TB drugs should be given until the patient fully recovers, followed by two drugs complete immunological reconstitution after HSCT is achieved. While there are no guidelines for CGD, prolonged therapy was not given. This may have been responsible for the increased mortality.

Genetic analysis of eight Sri Lankan CGD patients revealed that two siblings (P-05 and P-06) had p47*phox* AR-CGD resulting from the prominent GT deletion in exon 2 of *NCF1* gene. The remaining six patients were classified as X-linked CGD. Five patients had previously described \[[@CR9]\] *CYBB* mutations. The splice site mutation (c.141+6T \> A) identified in the remaining patient (P-07) was a novel mutation. Splice site mutations have been known to be responsible for many genetic diseases including β-thalassemia and CGD \[[@CR23]\]. Mutations located in both donor and acceptor splice sites may results in exon skipping and shortened polypeptides. Splice site mutations appear to be a common cause of X-linked CGD with 17.6% of 681 reported mutations falling into this category \[[@CR9]\].

The investigators encountered several limitations during the study which are worth mentioning. The Immunodeficiency Clinic at the MRI in Colombo is the sole clinic of its kind to diagnose CGD and other immunological disorders. Patients are referred from across the country to be investigated and diagnosed. The authors believe the prevalence of CGD in the country could be higher, and that a percentage of patients remain unreported and undiagnosed. Paucity of knowledge about primary immune deficiency among medical staff is one problem. Lack of resources to investigate and accurately diagnose infectious pathogens especially BCG disease and TB has contributed to the high mortality rate.

The CGD diagnosis in this study was based on the qualitative slide NBT assay. This assay is now being replaced by the flow cytometry based Dihydrorodemine (DHR) assay as the slide NBT assay is prone to observer bias and requires expertise. The DHR assay has not yet been established and validated in the country due to lack of resources. Furthermore, only eight patients of the cohort were sequenced. Four out of the five remaining patients could not be sequenced as they were already deceased by the time the genetic assay was established and validated, whereas the remaining patient is yet to be sequenced.

Conclusions {#Sec12}
===========

The Sri Lankan CGD patient cohort displayed classic clinical manifestation associated with CGD with pulmonary infections being the most common. Patients suffered recurrent severe infection despite using anti-microbial prophylaxis. Mycobacterial infections are potentially lethal in CGD patients and BCG vaccination should be avoided in infants with the disease. Despite the low number of patients to draw definite conclusions, mortality rate in Sri Lankan cohort remains high. The onset of disease and age at diagnosis is low in comparison to regional countries. Furthermore, the findings support the notion that X-linked CGD manifests earlier and is more severe than AR-CGD. An important highlight of the study was the identification of a novel *CYBB* pathogenic mutation.
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